Jazz Pharmaceuticals (JAZZ) Cash from Investing Activities (2010 - 2026)

Jazz Pharmaceuticals' Cash from Investing Activities history runs 17 years deep, the most recent figure standing at $123.1 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 172.84% year-over-year to $123.1 million in Q1 2026; TTM through Mar 2026 was -$1.2 billion, a 200.48% decrease from a year earlier, with the FY2025 full-year figure at -$1.5 billion, down 197.11% from the prior year.
• Cash from Investing Activities grew to $123.1 million in Q1 2026 per JAZZ's latest filing, from -$372.2 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $214.1 million in Q3 2024 and bottomed at -$641.0 million in Q2 2025.
• The 5-year median for Cash from Investing Activities is -$169.0 million (2025), against an average of -$147.3 million.
• Biggest YoY gain for Cash from Investing Activities was 222.83% in 2024; the steepest drop was 5538.82% in 2024.
• Year by year, Cash from Investing Activities stood at -$324.4 million in 2022, then jumped by 131.38% to $101.8 million in 2023, then tumbled by 289.87% to -$193.3 million in 2024, then slumped by 92.54% to -$372.2 million in 2025, then soared by 133.08% to $123.1 million in 2026.
• Per Business Quant, the three latest JAZZ Cash from Investing Activities figures stand at $123.1 million (Q1 2026), -$372.2 million (Q4 2025), and -$327.8 million (Q3 2025).